The Bristol Myers Squibb Foundation

Global Health | Global Impact


Our vision

At the Bristol Myers Squibb Foundation, our vision is to help create a world where everyone has the opportunity to achieve their optimal health. We strive to bridge divides by empowering local communities and health systems to create lasting impact.


Our mission

Our mission is to improve global health. We do this by improving access to healthcare for underserved populations, by engaging in partnerships that build capacity and strengthen health systems in the geographies where we work, from India to ten countries in Sub-Saharan Africa, to Brazil, and across the United States.


A legacy of impact

The BMS Foundation is continuing our decades long legacy of creating impact with our grantees to effect sustainable change.

Our signature programs & focus areas

Adult Cancers: Multinational Lung Cancer Control Program (MLCCP) and Adult Cancer Disparities

This signature program leverages lessons from our decade of work addressing lung cancer disparities in the US and focuses on building the capacity to better diagnose and treat lung cancer, while we remain committed to other high disease burden cancers prevalent in the countries where we are working.

Pediatric Cancers and Blood Disorders:​ Global HOPE (Hematology Oncology Pediatric Excellence)

This work is aligned with the BMS Pediatric Center of Excellence’s Mission “to be one of the world’s leading biopharma companies that transform pediatric patients’ lives through science”, with a commitment to being a leader in the wider pediatric community. This work includes pediatric cancers, sickle cell disease, and beta thalassemia​.

Neuropsychiatry: Mental Health Diversion Program

Our newest grant program in the US, focused on schizophrenia, supports the diversion of patients with serious mental illness from the criminal justice system into critical community-based mental health services.

Inclusion in Clinical Trials:​ Robert A. Winn Diversity in Clinical Trials Award Program

The Winn Award Program addresses the priority of increasing inclusion in clinical trials. By training the next generation of clinical trialists in the science of community engagement, we believe we can include more patients in clinical trials that match the epidemiology of the disease studied. Research areas include cancer, cardiovascular disease, and neuropsychiatry.

Global impact

United States


Adult cancers

  • Lung cancer 

Neuropsychiatry

  • Schizophrenia

Inclusion in clinical trials

  • Robert A. Winn Diversity in Clinical Trials Award Program
Brazil


Adult cancers

  • Lung cancer
  • Cervical cancer
  • Breast cancer
  • Prostate cancer

 

Sub-Saharan Africa

Adult cancers

  • Lung cancer 
  • Multiple myeloma
  • Cervical cancer

Pediatric cancers and blood disorders

 

India


Adult cancers

  • Lung cancer
Pediatric blood disorders
  • Beta thalassemia